A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer.

Research paper by Jung Sun JS Kim, Koung Jin KJ Suh, Dae-Won DW Lee, Go-Un GU Woo, Miso M Kim, Se Hyun SH Kim, Han Suk HS Ryu, Kyung-Hun KH Lee, Tae-Yong TY Kim, Sae-Won SW Han, So Yeon SY Park, In Ae IA Park, Jee Hyun JH Kim, Seock-Ah SA Im

Indexed on: 21 Aug '21Published on: 21 Aug '21Published in: Cancer research and treatment : official journal of Korean Cancer Association


We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients. This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled. A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of 4 prior lines of chemotherapy (4.5 lines when including endocrine therapy), and 66 (64.7%) patients were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 (35.3%) patients were Luminal A, 28 (27.5%) were Luminal B, 18 (17.7%) were HER2-positive, and 20 (19.6%) had triple-negative disease. Fifty (49.0%) patients were treated with a 3-weekly regimen (260 mg/m2 on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m2 every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% CI, 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p<0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction. This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.